Innovent's DOVBLERON Secures Second NMPA Approval for ROS1-Positive NSCLC
China's National Medical Products Administration (NMPA) has approved the second New Drug Application (NDA) of DOVBLERON®, a next-generation ROS1 tyrosine kinase inhibitor (TKI).
Innovent Biologics | 03/01/2025 | By Abha
Mankind Pharma, Innovent Biologics to Commercialize Sintilimab for Cancer Care
This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region.
Innovent Biologics | 27/12/2024 | By Aishwarya
Innovent Partners with Ask Pharm for Limertinib for Treatment of Lung Cancer
Under the agreement, Innovent will obtain the exclusive commercialization rights for limertinib in mainland China, and will be entitled to receive a commercialization service fee based on the product's net sales in the region.
Innovent Biologics | 08/10/2024 | By Aishwarya
Innovent Secures Fast Track Designation from FDA for IBI363
Innovent Biologics has announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to its PD-1/IL-2α Bispecific Antibody Fusion Protein for the treatment of unresectable locally advanced or metastatic melanoma.
Innovent Biologics | 04/09/2024 | By Aishwarya
Innovent and WeComput to Accelerate AI-Driven Drug Discovery and Development
Innovent Biologics, Inc. has forged a strategic partnership with WeComput to jointly advance the construction and improvement of Innovent Biologics' Artificial Intelligence for Drug Discovery platform.
Innovent Biologics | 26/07/2024 | By Aishwarya
Innovent Signs Agreement with IASO Bio for Cell Therapy
Innovent Biologics, Inc. and IASO Biotechnology have signed an agreement on a series of cooperation, including IASO Bio's purchase from Innovent regarding its relevant right of FUCASO (Equecabtagene Autoleucel) and obtaining license from Innovent regarding the intellectual property related to FUCASO, as well as Innovent's equity investment in IASO Bio.
Innovent Biologics | 06/07/2024 | By Aishwarya | 189
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy